Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II adjuvant durvalumab and tremelimumab with or without capecitabine for biliary tract cancer
2021-002389-41Phase 2Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Feb 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of durvalumab, tremelimumab and capecitabine in biliary cancer and cholangiocarcinoma (CCA) (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Recurrence-free survival at 12 months. Started Feb 2022; status: active.
02
Drugs
durvalumabtremelimumabcapecitabine
03
Conditions
biliary cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2021-002389-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002389-41.